Hasan Özen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hasan Özen has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Tanıl Kendirli
Department of Pediatric Critical Care, Ankara University School of Medicine, Ankara, Türkiye
16 shared publications - Anar Gurbanov
Department of Pediatric Critical Care Medicine, Ankara University Faculty of Medicine, Ankara, Turkey
15 shared publications - Emrah Gün
Division of Pediatric Critical Care Etlik City Hospital Ankara Turkey
15 shared publications - Edin Botan
Division of Pediatric Intensive Care, Department of Pediatrics, Ankara University School of Medicine, Ankara, Türkiye
14 shared publications - Burak Balaban
Division of Pediatrics, Department of Pediatric Intensive Care, Ankara University Faculty of Medicine, Ankara, Turkey
12 shared publications - Fevzi Kahveci
Division of Pediatric Intensive Care, Department of Pediatrics, Ankara University Faculty of Medicine, Türkiye
12 shared publications
Latest Publications
- 13 October 2026
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 29 (4) , 70
Successful management of long-term venovenous ECMO for severe PARDS in a child with acute lymphoblastic leukemia
Pediatric acute respiratory distress syndrome (PARDS) is an important cause of morbidity and mortality in pediatric intensive care units. We report successful prolonged venovenous extracorporeal membrane oxygenation (VV-ECMO) support in a child with severe PARDS and acute lymphoblastic leukemia (ALL). A 5-year-old boy with low-risk B-cell ALL developed severe refractory PARDS during induction therapy. VV-ECMO was initiated for profound hypoxemia and continued for 34 days, after which he was successfully decannulated. He was discharged after 235 days of hospitalization. This case suggests that prolonged VV-ECMO may be a feasible rescue strategy in carefully selected children with ALL when respiratory failure is potentially reversible and the oncological prognosis is favorable.
- 13 October 2026
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 29 (4) , 70
Successful management of long-term venovenous ECMO for severe PARDS in a child with acute lymphoblastic leukemia
Pediatric acute respiratory distress syndrome (PARDS) is an important cause of morbidity and mortality in pediatric intensive care units. We report successful prolonged venovenous extracorporeal membrane oxygenation (VV-ECMO) support in a child with severe PARDS and acute lymphoblastic leukemia (ALL). A 5-year-old boy with low-risk B-cell ALL developed severe refractory PARDS during induction therapy. VV-ECMO was initiated for profound hypoxemia and continued for 34 days, after which he was successfully decannulated. He was discharged after 235 days of hospitalization. This case suggests that prolonged VV-ECMO may be a feasible rescue strategy in carefully selected children with ALL when respiratory failure is potentially reversible and the oncological prognosis is favorable.
- Open Access
- 12 October 2026
- Published by Springer Nature in BMC Pediatrics
Use of methylene blue in the management of refractory shock in pediatric intensive care units: a nationwide assessment of clinical practice in Türkiye
- 12 October 2026
- Published by Springer Nature in BMC Pediatrics
Open AccessUse of methylene blue in the management of refractory shock in pediatric intensive care units: a nationwide assessment of clinical practice in Türkiye
- Open Access
- 26 August 2026
- Published by Caleo in Turkish Archives of Pediatrics
Impact of Immunotherapy Combinations on Clinical Outcomes in Children with Acute Flaccid Paralysis: A Multicenter Intensive Care Study
Objective: Acute flaccid paralysis (AFP) is a syndrome characterized by the rapid onset of limb weakness and decreased muscle tone, frequently accompanied by respiratory or bulbar involvement. Methods: This retrospective multicenter study evaluated the clinical characteristics, treatment modalities, intensive care processes, and outcomes of 68 children diagnosed with AFP who were admitted to pediatric intensive care units (PICUs) between January 1, 2018, and January 1, 2023. Results: The patients’ ages ranged from 1 month to 18 years (mean 7.9 ± 4.5 years), and 33 (48.5%) were male. The mean PICU stay was 15.4 ± 19.5 days, and the mean total hospital stay was 23.3 ± 21.1 days. Respiratory support was required in 42 patients (61.8%). All patients received intravenous immunoglobulin (IVIG). Therapeutic plasma exchange (TPE) was administered to 25 of 43 Guillain–Barré syndrome (GBS) patients, 7 of 11 transverse myelitis (TM) patients, and 11 of 14 acute disseminated encephalomyelitis (ADEM) patients. Among 14 intubated GBS patients, 5 received IVIG for ≤2 days and 9 for ≥4 days. The duration of invasive mechanical ventilation (MV) was significantly longer in patients receiving IVIG for ≥4 days (P=.044). Guillain–Barré syndrome patients treated with combined IVIG and TPE had longer PICU stays compared with those receiving IVIG alone (P=.001). Conclusion: Combination immunotherapies were associated with longer MV duration and PICU stay compared with monotherapy in AFP patients. In intubated GBS patients, administration of IVIG over 2 days was associated with a shorter duration of invasive MV.
- 26 August 2026
- Published by Caleo in Turkish Archives of Pediatrics
Open AccessImpact of Immunotherapy Combinations on Clinical Outcomes in Children with Acute Flaccid Paralysis: A Multicenter Intensive Care Study
Objective: Acute flaccid paralysis (AFP) is a syndrome characterized by the rapid onset of limb weakness and decreased muscle tone, frequently accompanied by respiratory or bulbar involvement. Methods: This retrospective multicenter study evaluated the clinical characteristics, treatment modalities, intensive care processes, and outcomes of 68 children diagnosed with AFP who were admitted to pediatric intensive care units (PICUs) between January 1, 2018, and January 1, 2023. Results: The patients’ ages ranged from 1 month to 18 years (mean 7.9 ± 4.5 years), and 33 (48.5%) were male. The mean PICU stay was 15.4 ± 19.5 days, and the mean total hospital stay was 23.3 ± 21.1 days. Respiratory support was required in 42 patients (61.8%). All patients received intravenous immunoglobulin (IVIG). Therapeutic plasma exchange (TPE) was administered to 25 of 43 Guillain–Barré syndrome (GBS) patients, 7 of 11 transverse myelitis (TM) patients, and 11 of 14 acute disseminated encephalomyelitis (ADEM) patients. Among 14 intubated GBS patients, 5 received IVIG for ≤2 days and 9 for ≥4 days. The duration of invasive mechanical ventilation (MV) was significantly longer in patients receiving IVIG for ≥4 days (P=.044). Guillain–Barré syndrome patients treated with combined IVIG and TPE had longer PICU stays compared with those receiving IVIG alone (P=.001). Conclusion: Combination immunotherapies were associated with longer MV duration and PICU stay compared with monotherapy in AFP patients. In intubated GBS patients, administration of IVIG over 2 days was associated with a shorter duration of invasive MV.
- Open Access
- 25 November 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 36 (Supplement) , S1-S38
Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome
Antispasmodics are commonly used to treat irritable bowel syndrome (IBS) symptoms. They are generally regarded as safe.However, some have been found to be ineffective or not cost-effective. Marked discrepancies in the availability and formulation of antispasmodic agents across countries—ranging from the limitation to only fundamental compounds in regions such as the United States to the marketing of diverse combination products elsewhere—have generated considerable ambiguity and debate within the field. Meta-analyses show varying results on the efficacy of antispasmodics, indicating the need for further analysis. This article aims to evaluate the effectiveness of antispasmodic drugs in relieving symptoms in IBS patients. We conclude that most drugs are considered safe and effective, with pinaverium, otilonium, and peppermint oil having meta-analyses supporting their efficacy. However, there is a lack of high-quality data for drugs like alverine, trimebutine, and cimetropium, and some drugs, such as simeticone or combinations of spasmolytic agents and simeticone, have insufficient research data. Clinicians should prioritize evidence-based medicine when selecting antispasmodic agents. Cite this article as: Bor S, Özen H, Akyüz F, et al. Expert opinion on the efficacy and safety of antispasmodics with a focus on irritable bowel syndrome. Turk J Gastroenterol. 2025;36(Supp 2):S1-S38.
- 25 November 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 36 (Supplement) , S1-S38
Open AccessExpert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome
Antispasmodics are commonly used to treat irritable bowel syndrome (IBS) symptoms. They are generally regarded as safe.However, some have been found to be ineffective or not cost-effective. Marked discrepancies in the availability and formulation of antispasmodic agents across countries—ranging from the limitation to only fundamental compounds in regions such as the United States to the marketing of diverse combination products elsewhere—have generated considerable ambiguity and debate within the field. Meta-analyses show varying results on the efficacy of antispasmodics, indicating the need for further analysis. This article aims to evaluate the effectiveness of antispasmodic drugs in relieving symptoms in IBS patients. We conclude that most drugs are considered safe and effective, with pinaverium, otilonium, and peppermint oil having meta-analyses supporting their efficacy. However, there is a lack of high-quality data for drugs like alverine, trimebutine, and cimetropium, and some drugs, such as simeticone or combinations of spasmolytic agents and simeticone, have insufficient research data. Clinicians should prioritize evidence-based medicine when selecting antispasmodic agents. Cite this article as: Bor S, Özen H, Akyüz F, et al. Expert opinion on the efficacy and safety of antispasmodics with a focus on irritable bowel syndrome. Turk J Gastroenterol. 2025;36(Supp 2):S1-S38.
- Open Access
- 15 April 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (9) , 4417-4425
Correlation between early computed tomography findings and neurological outcome in pediatric traumatic brain injury patients
Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in children. Head computed tomography (CT) is frequently utilized for evaluating trauma-related characteristics, selecting treatment options, and monitoring complications in the early stages. This study assessed the relationship between cranial CT findings and early and late neurological outcomes in pediatric TBI patients admitted to the pediatric intensive care unit (PICU). The study included children aged 1 month to 18 years who were admitted to the PICU due to TBI between 2014 and 2020. Sociodemographic data, clinical characteristics, and cranial CT findings were analyzed. Patients were categorized based on their Glasgow Coma Scale (GCS) score. Of the 129 patients, 83 (64%) were male, and 46 (36%) were female, with a mean age of 6.8 years. Falls (n = 51, 39.5%) and in-vehicle traffic accidents (n = 35, 27.1%) were the most common trauma types observed. Normal brain imaging findings were found in 62.7% of the patients, while 37.3% exhibited intracranial pathology. Hemorrhage was the most frequent CT finding. Severe TBI (n = 26, p = 0.032) and mortality (n = 9, p = 0.017) were more prevalent in traffic accidents. The overall mortality rate in the study population was 10.1%. In children with TBI, cranial CT imaging serves as an essential initial method for patients with neurological manifestations. Particularly, a GCS score of ≤ 8, multiple hemorrhages, diffuse cerebral edema, and intraventricular bleeding are associated with sequelae and mortality.
- 15 April 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (9) , 4417-4425
Open AccessCorrelation between early computed tomography findings and neurological outcome in pediatric traumatic brain injury patients
Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in children. Head computed tomography (CT) is frequently utilized for evaluating trauma-related characteristics, selecting treatment options, and monitoring complications in the early stages. This study assessed the relationship between cranial CT findings and early and late neurological outcomes in pediatric TBI patients admitted to the pediatric intensive care unit (PICU). The study included children aged 1 month to 18 years who were admitted to the PICU due to TBI between 2014 and 2020. Sociodemographic data, clinical characteristics, and cranial CT findings were analyzed. Patients were categorized based on their Glasgow Coma Scale (GCS) score. Of the 129 patients, 83 (64%) were male, and 46 (36%) were female, with a mean age of 6.8 years. Falls (n = 51, 39.5%) and in-vehicle traffic accidents (n = 35, 27.1%) were the most common trauma types observed. Normal brain imaging findings were found in 62.7% of the patients, while 37.3% exhibited intracranial pathology. Hemorrhage was the most frequent CT finding. Severe TBI (n = 26, p = 0.032) and mortality (n = 9, p = 0.017) were more prevalent in traffic accidents. The overall mortality rate in the study population was 10.1%. In children with TBI, cranial CT imaging serves as an essential initial method for patients with neurological manifestations. Particularly, a GCS score of ≤ 8, multiple hemorrhages, diffuse cerebral edema, and intraventricular bleeding are associated with sequelae and mortality.
- Open Access
- 2 January 2024
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 59 (1) , 112-113
Successful Treatment with Ascorbic Acid in a Case of Methemoglobinemia Due to Glucose-6-Phosphate Dehydrogenase Deficiency
Cite this article as: Karaçoban G, Gurbanov A, Özen H, Gün E, Çakmaklı HF, Kendirli T. Successful treatment with ascorbic acid in a case of methemoglobinemia due to glucose-6-phosphate dehydrogenase deficiency. Turk Arch Pediatr. 2024;59(1):112-113.
- 2 January 2024
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 59 (1) , 112-113
Open AccessSuccessful Treatment with Ascorbic Acid in a Case of Methemoglobinemia Due to Glucose-6-Phosphate Dehydrogenase Deficiency
Cite this article as: Karaçoban G, Gurbanov A, Özen H, Gün E, Çakmaklı HF, Kendirli T. Successful treatment with ascorbic acid in a case of methemoglobinemia due to glucose-6-phosphate dehydrogenase deficiency. Turk Arch Pediatr. 2024;59(1):112-113.
- 29 December 2023
- Published by Galenos Yayinevi in Turkish Journal of Clinical Cardiovascular Perfusion
- Vol. 1 (3) , 111-114
Successful Extracorporeal Cardiopulmonary Resuscitation in a Case of Severe Tracheal Stenosis after Congenital Heart Surgery
- 29 December 2023
- Published by Galenos Yayinevi in Turkish Journal of Clinical Cardiovascular Perfusion
- Vol. 1 (3) , 111-114
Successful Extracorporeal Cardiopulmonary Resuscitation in a Case of Severe Tracheal Stenosis after Congenital Heart Surgery
- Open Access
- 31 October 2023
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 58 (6) , 600-606
Venovenous Versus Venoarterial Extracorporeal Membrane Oxygenation: Pediatric Acute Respiratory Distress Syndrome
Objective: This study aimed to compare the efficacy, complication, and mortality of patients who were supported by venovenous (VV) extracorporeal membrane oxygenation (ECMO) and venoarterial (VA) ECMO for pediatric acute respiratory distress syndrome (PARDS). Materials and Methods: This study is a single-center, retrospective cohort study between 2014 and 2022. We evaluated to indication of ECMO support, ECMO type, patients’ demographic features, complications, and children's outcomes supported by ECMO for PARDS. Results: Twenty-two patients with PARDS, 12 (54%) with VV, and 10 (46%) with VA ECMO were selected. The median number of days to be intubated before ECMO cannulation was 5 (0-16) days. The distribution of intubated days before the patients underwent ECMO was as follows: 0-1 days, 7 (31.8%) patients; 2-3 days, 2 (9.1%) patients; 4-7 days, 7 (31.8%) patients; 8-14 days, 5 (22.8%) patients; >14 days, 1 (4.5%) patient. The median ECMO cannulation day after admission to the pediatric intensive care unit was 3 (range, 1-9) days in the VV ECMO patient group, whereas it was 8 (range, 0-19) days in the VA ECMO group (P = .02). Considering hospital survival, 4 (45%) patients who underwent double-lumen VV ECMO, 1 (33%) patient who underwent VV ECMO, and 3 (30%) patients who supported by VAECMO survived. There was no difference between the groups in terms of hospital discharge rates. Conclusion: The highest survival rate was found in the VV ECMO patient group established with double-lumen cannulas, similar to the literature. There was no difference in mortality between the groups whose intubation time before ECMO was 14 days or less. Cite this article as: Kahveci F, Karaçoban G, Çelik NA, et al. Venovenous versus venoarterial extracorporeal membrane oxygenation: Pediatric acute respiratory distress syndrome. Turk Arch Pediatr. 2023;58(6):600-606.
- 31 October 2023
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 58 (6) , 600-606
Open AccessVenovenous Versus Venoarterial Extracorporeal Membrane Oxygenation: Pediatric Acute Respiratory Distress Syndrome
Objective: This study aimed to compare the efficacy, complication, and mortality of patients who were supported by venovenous (VV) extracorporeal membrane oxygenation (ECMO) and venoarterial (VA) ECMO for pediatric acute respiratory distress syndrome (PARDS). Materials and Methods: This study is a single-center, retrospective cohort study between 2014 and 2022. We evaluated to indication of ECMO support, ECMO type, patients’ demographic features, complications, and children's outcomes supported by ECMO for PARDS. Results: Twenty-two patients with PARDS, 12 (54%) with VV, and 10 (46%) with VA ECMO were selected. The median number of days to be intubated before ECMO cannulation was 5 (0-16) days. The distribution of intubated days before the patients underwent ECMO was as follows: 0-1 days, 7 (31.8%) patients; 2-3 days, 2 (9.1%) patients; 4-7 days, 7 (31.8%) patients; 8-14 days, 5 (22.8%) patients; >14 days, 1 (4.5%) patient. The median ECMO cannulation day after admission to the pediatric intensive care unit was 3 (range, 1-9) days in the VV ECMO patient group, whereas it was 8 (range, 0-19) days in the VA ECMO group (P = .02). Considering hospital survival, 4 (45%) patients who underwent double-lumen VV ECMO, 1 (33%) patient who underwent VV ECMO, and 3 (30%) patients who supported by VAECMO survived. There was no difference between the groups in terms of hospital discharge rates. Conclusion: The highest survival rate was found in the VV ECMO patient group established with double-lumen cannulas, similar to the literature. There was no difference in mortality between the groups whose intubation time before ECMO was 14 days or less. Cite this article as: Kahveci F, Karaçoban G, Çelik NA, et al. Venovenous versus venoarterial extracorporeal membrane oxygenation: Pediatric acute respiratory distress syndrome. Turk Arch Pediatr. 2023;58(6):600-606.
- 4 October 2023
- Published by Galenos Yayinevi in Turkish Journal of Pediatric Emergency and Intensive Care Medicine
- Vol. 10 (3) , 198-204
Comparison of Citrate and Heparin for Continuous Renal Replacement Therapy in Pediatric Intensive Units
- 4 October 2023
- Published by Galenos Yayinevi in Turkish Journal of Pediatric Emergency and Intensive Care Medicine
- Vol. 10 (3) , 198-204
Comparison of Citrate and Heparin for Continuous Renal Replacement Therapy in Pediatric Intensive Units
- Open Access
- 31 August 2023
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 38 (3) , 371-379
Impact of the COVID-19 pandemic on diabetic ketoacidosis management in the pediatric intensive care unit
Background: Diabetic ketoacidosis (DKA) is a common endocrine emergency in pediatric patients. Early presentation to health facilities, diagnosis, and good management in the pediatric intensive care unit (PICU) are crucial for better outcomes in children with DKA. Methods: This was a single-center, retrospective cohort study conducted between February 2015 and January 2022. Patients with DKA were divided into two groups according to pandemic status and diabetes diagnosis. Both groups were examined in two subcategories (pandemic status: pre-pandemic vs. pandemic; and diabetes diagnosis status: previously diagnosed vs. newly diagnosed).Results: The study enrolled 59 patients, and their mean age was 11±5 years. Forty (68%) had newly diagnosed type 1 diabetes mellitus (T1DM), and 61% received follow-up in the pre-pandemic period. Blood glucose, blood ketone, potassium, phosphorus, creatinine, and alanine transaminase levels were significantly higher in the new-onset T1DM group compared with the previously diagnosed group (P=0.01, P=0.02, P=0.01, P=0.039, and p=0.001, respectively). In patients with newly diagnosed T1DM, length of PICU stays were longer than in those with previously diagnosed T1DM (28.5±8.9 vs. 17.3±6.7 hours, p<0.005). The pandemic group was compared with pre-pandemic group, there was a statistically significant difference in laboratory parameters of pH, HCO3, and lactate and also Pediatric Risk Of Mortality (PRISM) III score. All patients survived, and there were no neurologic sequelae. Conclusion: Patients admitted during the pandemic period were admitted with more severe DKA and had higher PRISM III scores. During the pandemic period, there was an increase in the incidence of DKA in the participating center compared to that before the pandemic. Although the reason for this is not fully known, it could be public health presentations were not effective during the coronavirus disease 2019 (COVID-19) period.
- 31 August 2023
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 38 (3) , 371-379
Open AccessImpact of the COVID-19 pandemic on diabetic ketoacidosis management in the pediatric intensive care unit
Background: Diabetic ketoacidosis (DKA) is a common endocrine emergency in pediatric patients. Early presentation to health facilities, diagnosis, and good management in the pediatric intensive care unit (PICU) are crucial for better outcomes in children with DKA. Methods: This was a single-center, retrospective cohort study conducted between February 2015 and January 2022. Patients with DKA were divided into two groups according to pandemic status and diabetes diagnosis. Both groups were examined in two subcategories (pandemic status: pre-pandemic vs. pandemic; and diabetes diagnosis status: previously diagnosed vs. newly diagnosed).Results: The study enrolled 59 patients, and their mean age was 11±5 years. Forty (68%) had newly diagnosed type 1 diabetes mellitus (T1DM), and 61% received follow-up in the pre-pandemic period. Blood glucose, blood ketone, potassium, phosphorus, creatinine, and alanine transaminase levels were significantly higher in the new-onset T1DM group compared with the previously diagnosed group (P=0.01, P=0.02, P=0.01, P=0.039, and p=0.001, respectively). In patients with newly diagnosed T1DM, length of PICU stays were longer than in those with previously diagnosed T1DM (28.5±8.9 vs. 17.3±6.7 hours, p<0.005). The pandemic group was compared with pre-pandemic group, there was a statistically significant difference in laboratory parameters of pH, HCO3, and lactate and also Pediatric Risk Of Mortality (PRISM) III score. All patients survived, and there were no neurologic sequelae. Conclusion: Patients admitted during the pandemic period were admitted with more severe DKA and had higher PRISM III scores. During the pandemic period, there was an increase in the incidence of DKA in the participating center compared to that before the pandemic. Although the reason for this is not fully known, it could be public health presentations were not effective during the coronavirus disease 2019 (COVID-19) period.